Management of antiretroviral failure and resistance in developing countries

Current Opinion in HIV and AIDS

Volumn 4, Issue 6, 2009, Pages 538-544

  Hawkins, Claudia ^a   Murphy, Robert L ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Antiretroviral therapy failure; Developing countries; Resistance

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE PLUS RITONAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; DIDANOSINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; THYMIDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

DRUG EFFICACY; DRUG TREATMENT FAILURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINASE INHIBITION; REVIEW; SENSITIVITY AND SPECIFICITY; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE; WORLD HEALTH ORGANIZATION;

ANTI-RETROVIRAL AGENTS; DEVELOPING COUNTRIES; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HUMANS; TREATMENT FAILURE;

EID: 70350159352     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328331d2fb     Document Type: Review

References (58)

1. 2008 Report on the Global AIDS Epidemic. (UNAIDS) Joint United Nations Programme on HIV/AIDS. http://www.unaids.org/en/KnowledgeCentre/ HIV Data/GlobalReport/2008/2008-Global-report.asp. Accessed April 30 2009.
2. Akileswaran C, Lurie MN, Flanigan TP, et al. Lessons learned from use of highly active antiretroviral therapy in Africa. CID 2005; 41:376-385.
3. Van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomized open-label trial, the 2NN Study. Lancet 2004; 363:1253-1263.
4. Yeni P, Cooper DA, Aboulker JP, et al. Virologic and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing nonnucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomized trial. Lancet 2006; 368:287-298.
5. Kamya MR, Mayanja-Kizza H, Kambugu A, et al. Academic alliance for AIDS care and prevention in Africa. Predictors of long-term viral failure among Ugandan children and adults treated with antiretroviral failure. J Acquir Immune Defic Syndr 2007; 46:187-193.
6. Pujades-Rodrýguez M, O'Brien D, Humblet P, Calmy A. Second line antiretroviral therapy in resource-limited settings: the experience of Mé decins Sans Frontiè res. AIDS 2008; 22:1305-1311.
7. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, et al. Options for a second line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007; 44:447-452.
8. Prioritizing second line antiretroviral drugs for adults and adolescents: a Public Health approach. Report of a WHO Working Group Meeting. WHO HIV Department. Geneva, Switzerland 21-22 May; 2007.
9. Maldonado F, Biot M, Roman F, et al. Viraemia and HIV-1 drug resistance mutations among patients receiving antiretroviral treatment in Mozambique. Trans R Soc Trop Med Hyg 2009; 103:607-612.
10. Spire B, Carrieri P, Sopha P, et al. Adherence to antiretroviral therapy in patients enrolled in a comprehensive care program in Cambodia: a 24-month follow-up assessment. Antivir Ther 2008; 13:697-703.
11. Chang LW, Alamo S, Guma S, et al. Two-year virologic outcomes of an alternative AIDS care model: evaluation of a peer health worker and nursestaffed community-based program in Uganda. J Acquir Immune Defic Syndr 2009; 50:276-282.
12. Marcelin AG, Jarrousse B, Derache A, et al. HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first line regimen. AIDS 2007; 21:2341-2343.
13. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. J Am Med Assoc 2006; 296:782-793.
14. Gupta R, Hill A, Sawyer AW, et al. Emergence of drug resistance in HIV type 1-infected patients after receipt of first line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis 2008; 47:712-722.
15. Antiretroviral therapy of HIV infection in adults and children in resource limited settings: recommendations for a public health approach.Geneva:WHO 2006. http://www.who.int/hiv/pub/guidelines/art/en/. Accessed April 30 2009.
16. Johnson VA, Brun-Vezinet F, Clotet B, et al., International AIDS Society-USA Drug Resistance Mutations Group. Update of the drug resistance mutations in HIV-1. Top HIV Med 2008; 16:138-145.
17. Gilliam BL, Sajadi MM, Amoroso A, et al. Tenofovir and abacavir combination therapy: lessons learned from an Urban Clinic Population. Bruce L AIDS Patient Care and STDS 2007; 21:240-246.
18. Barrios A, Rendó n A, Negredo E, et al. Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. AIDS 2005; 19:569-575.
19. Bennett DE, Bertagnolio S, Sutherland D, et al. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther 2008; 13:1-13.
20. Gallant JE. Drug resistance after failure of initial antiretroviral therapy in resource-limited countries. Clin Infect Dis 2007; 44:453-455.
21. Zhou J, Paton NI, Ditangco R, et al. Experience with the use of a first line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database. HIV Med 2007; 8:8-16.
22. Bussman H, Wester W, Thomas A, et al. Response to zidovudine/ didanosinecontaining combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial. J Acquir Immune Defic Syndr 2009; 51:37-46.
23. Keiser O (editor). Switching to second line ART, and mortality in resourcelimited settings: collaborative analysis of treatment programs in Africa, Asia and Latin America.16th Conference on Retroviruses and Opportunistic Infections, Feb 8-11th, Montreal, Canada; 2009.
24. Collini P, Schwab U, Sarfo S, et al. Sustained immunological responses to highly active antiretroviral therapy at 36 months in a Ghanaian HIV cohort. Clin Infect Dis 2009; 48:988-991.
25. Palombi L, Marazzi MC, Guidotti G, et al. DREAM Program. Incidence and predictors of death, retention, and switch to second line regimens in antiretroviral- treated patients in Sub-Saharan African Sites with comprehensive monitoring availability. Clin Infect Dis 2009; 48:115-122.
26. Vasan A, Hoos D, Mukherjee JS, et al. The pricing and procurement of antiretroviral drugs: an observational study of data from the Global Fund. Bull World Health Organ 2006; 84:393-398.
27. Orrell C, Harling G, Lawn SD, et al. Conservation of first line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther 2007; 12:83-88.
28. Boesecke C, Cooper DA. Toxicity of HIV protease inhibitors: clinical considerations. Curr Opin HIV AIDS 2008; 3:653-659.
29. Bisson GP, Gross R, Strom JB, et al. Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy. AIDS 2006; 20:1613-1619.
30. Reynolds SJ, Nakigozi G, Newell K, et al. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS 2009; 23:697-700.
31. Moore DM, Mermin J, Awor A, et al. Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings. J Acquir Immune Defic Syndr 2006; 43:436-439.
32. Rewari B (editor). Evaluating patients for second line ART in India: confirmation of virological failure prevents unnecessary treatment switches. 16th Conference on Retroviruses and Opportunistic Infections, Feb 8-11th, Montreal, Canada; 2009.
33. Etiebet M-A (editor). Performance of WHO immunological criteria for determining virological treatment failure in low-resource settings. 16th Conference on Retroviruses and Opportunistic Infections, Feb 8-11th, Montreal, Canada; 2009.
34. Mee P, Fielding KL, Charalambous S, et al. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 2008; 22:1971-1977.
35. Hosseinipour MC, van Oosterhout JJG, Weigel R, et al. The public health approach to identify therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first line antiretroviral therapy. AIDS 2009; 23:1127-1134.
36. Petersen ML, van der Laan MJ, Napravnik S, et al. Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS 2008; 22:2097-2106.
37. Marconi VC, Sunpath H, Lu Z, Gordon M, et al., South Africa Resistance Cohort Study Team. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis 2008; 46:1589-1597.
38. DART Virology Group and Trial Team. Virological response to a triple nucleoside/ nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 2006; 20:1391-1399.
39. Gody JC, Charpentier C, Mbitikon O, et al. High prevalence of antiretroviral drug resistance mutations in HIV-1 non-B subtype strains from African children receiving antiretroviral therapy regimen according to the 2006 revised WHO recommendations. J Acquir Immune Defic Syndr 2008; 49: 566-569.
40. Laurent C, Bourgeois A, Mpoudi-Ngolé E, et al. Tolerability and effectiveness of first line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon. AIDS Res Hum Retroviruses 2008; 24:393-399.
41. Ferradini L, Jeannin A, Pinoges L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 2006; 367:1335-1342.
42. Sow P (editor). AIDS as a chronic disease in Africa: a 10-year follow-up of patients under ART in Senegal. 16th Conference on Retroviruses and Opportunistic Infections, Feb 8-11th, Montreal, Canada; 2009.
43. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-260.
44. Parikh UM, Barnas DC, Faruki H, et al. Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level. J Infect Dis 2006; 194:651-660.
45. ART Cohort Collaboration (ART-CC) groups. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817-824.
46. Coutinho A (editor). Utility of routine viral load, CD4 cell count, and clinical monitoring among HIV-infected adults in Uganda: a randomized trial. 15th Conference on Retroviruses and Opportunistic Infections, Feb 3-6th, Boston, MA; 2008.
47. Moore DM, Mermin J. Monitoring antiretroviral failure in resource-poor settings. Lancet 2008; 371:1396-1397.
48. Hosseinipour M (editor). Clinical, immunological, and virological outcomes of second line treatment, Malawi. 16th Conference on Retroviruses and Opportunistic Infections, Feb 8-11th, Montreal, Canada; 2009.
49. Fox M (editor). Clinical outcomes on second line antiretroviral therapy in a large urban clinic in Johannesburg, South Africa.
50. Arribas JR, Delagado R, Arranz A, et al., OK04 Study Group. Lopinavirritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. J Acquir Immune Defic Syndr 2009; 51:147-215.
51. Calmy A, Ford N, Hirschel B, et al. HIV viral load monitoring in resourcelimited regions: optional or necessary? Clin Infect Dis 2007; 44:128-134.
52. Maphalala G, Okello V, Mndzebele S, Gwebu P, et al. Surveillance of transmitted HIV drug resistance in the Manzini-Mbabane corridor, Swaziland, in 2006. Antivir Ther 2008; 13:95-100.
53. Somi GR, Kibuka T, Diallo K, et al. Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania. Antivir Ther 2008; 13:77-82.
54. Doualla-Bell F, Avalos A, Brenner B, et al. High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother 2006; 50:4182-4185.
55. Eshleman SH, Hoover DR, Chen S, et al. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis 2005; 192:30-36.
56. Sanne I, Piliero P, Squires K, et al., AI424-007 Clinical Trial Group. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 2003; 32:18-29.
57. Ledergerber B, Lundgren JD, Walker AS, et al., PLATO Collaboration. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1 infected individuals with antiretroviral failure to all three antiretroviral classes. Lancet 2004; 364:51-62.
58. Van Roey J, Von Schoen-Angerer T, Ford N, Calmy A. How developing world concerns need to be part of drug development plans: a case study of four emerging antiretrovirals. Drug Discov Today 2008; 13:601-605.